PMV PHARMACEUTICALS INC. - COMMON STOCK

PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results

07 Nov 2024 08:00:01 By Nasdaq GlobeNewswire

PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial

23 Oct 2024 08:00:01 By Nasdaq GlobeNewswire

PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial

08 Aug 2024 08:00:01 By Nasdaq GlobeNewswire

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June

30 May 2024 07:00:00 By Nasdaq GlobeNewswire

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

29 May 2024 07:00:00 By Nasdaq GlobeNewswire

PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights

09 May 2024 08:00:00 By Nasdaq GlobeNewswire

PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors

27 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer

18 Mar 2024 16:01:00 By Nasdaq GlobeNewswire

PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights

29 Feb 2024 16:01:00 By Nasdaq GlobeNewswire

PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference

26 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway

18 Jan 2024 16:01:00 By Nasdaq GlobeNewswire

PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development

05 Jan 2024 16:01:00 By Nasdaq GlobeNewswire

PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights

09 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation

12 Oct 2023 12:30:00 By Nasdaq GlobeNewswire

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar

11 Oct 2023 12:00:00 By Nasdaq GlobeNewswire

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

20 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights

09 Aug 2023 08:00:01 By Nasdaq GlobeNewswire

PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference

06 Jun 2023 16:01:00 By Nasdaq GlobeNewswire

PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights

10 May 2023 08:00:01 By Nasdaq GlobeNewswire

PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights

01 Mar 2023 08:00:02 By Nasdaq GlobeNewswire